⚠ Disclaimer: This report is generated using AI tools and is for informational purposes only. It does not constitute investment advice. Please consult a registered financial advisor before making any investment decisions.
LALPATHLAB - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 4.0
| Stock Code | LALPATHLAB | Market Cap | 22,489 Cr. | Current Price | 1,344 ₹ | High / Low | 1,771 ₹ |
| Stock P/E | 41.9 | Book Value | 140 ₹ | Dividend Yield | 0.89 % | ROCE | 30.6 % |
| ROE | 24.7 % | Face Value | 10.0 ₹ | DMA 50 | 1,406 ₹ | DMA 200 | 1,463 ₹ |
| Chg in FII Hold | -1.57 % | Chg in DII Hold | 0.98 % | PAT Qtr | 113 Cr. | PAT Prev Qtr | 146 Cr. |
| RSI | 41.5 | MACD | -18.5 | Volume | 1,76,551 | Avg Vol 1Wk | 2,47,794 |
| Low price | 1,176 ₹ | High price | 1,771 ₹ | PEG Ratio | 3.21 | Debt to equity | 0.06 |
| 52w Index | 28.2 % | Qtr Profit Var | 7.24 % | EPS | 30.8 ₹ | Industry PE | 32.6 |
📊 Core Financials
- Revenue Growth: PAT declined (₹113 Cr vs ₹146 Cr), showing earnings pressure
- Profit Margins: EPS ₹30.8, strong profitability
- Debt Ratio: Very low leverage (Debt-to-Equity 0.06)
- Cash Flows: Stable, supported by consistent healthcare demand
- Return Metrics: ROCE 30.6%, ROE 24.7% — excellent efficiency
💹 Valuation Indicators
- P/E Ratio: 41.9 (above industry PE of 32.6, slightly overvalued)
- P/B Ratio: ~9.6 (premium valuation)
- PEG Ratio: 3.21 (growth priced expensively)
- Intrinsic Value: Current price ₹1,344 is near support (₹1,176), offering cautious entry
🏢 Business Model & Competitive Advantage
- Leading diagnostic and pathology services provider in India
- Strong brand recognition and extensive network of labs
- Debt-free balance sheet enhances resilience
- Dividend yield of 0.89% provides modest shareholder return
📈 Entry Zone & Long-Term Guidance
- Entry Zone: ₹1,300–₹1,350 range (near support levels)
- Long-Term Holding: Attractive due to strong efficiency and healthcare demand
- Risk: Premium valuation and declining PAT may limit short-term upside
✅ Positive
- Strong ROCE and ROE metrics compared to peers
- Low debt ensures financial stability
- DII holdings increased (+0.98%), showing domestic investor confidence
⚠️ Limitation
- P/E ratio higher than industry average
- PEG ratio indicates growth is priced expensively
- Quarterly PAT declined from ₹146 Cr to ₹113 Cr
📰 Company Negative News
- Decline in FII holdings (-1.57%) shows reduced foreign investor confidence
- Stock trading below DMA 50 & DMA 200, showing weak momentum
🌟 Company Positive News
- DII holdings increased (+0.98%), showing domestic investor support
- Strong EPS of ₹30.8 supports valuation
🏦 Industry
- Diagnostics and healthcare sector with strong long-term demand
- Industry PE at 32.6, LALPATHLAB trades above this, showing premium valuation
- Sector growth supported by rising healthcare awareness and preventive testing
🔎 Conclusion
- LALPATHLAB is financially strong with excellent ROE/ROCE and low debt
- Valuation is slightly expensive compared to industry peers
- Entry near ₹1,300–₹1,350 is favorable for long-term investors
- Best suited for portfolios seeking healthcare exposure with moderate risk tolerance